NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.377) was uploaded to the NHS England Website on Thursday 13, November 2025.
The following changes have been introduced:
Glofitamab in combinaton with gemcitabine and oxaliplatin (GLO2)
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B- cell lymphoma where the following criteria have been met
Recommended for routine commissioning, receiving CDF interim funding
Atezolizumab (ATE9)
Atezolizumab monotherapy for the first line treatment of locally advanced or metastatic non-small cell lung cancer which has PD-L1 expression in at least 50% of tumour cells or in at least 10% of tumour-infiltrating immune cells where the following criteria are met:
Treatment criteria (#6 and 12) updated
Blinatumomab (BLI2)
The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients
Treatment criteria (#5, 7 and 10) updated
Blinatumomab (BLI3)
The treatment of patients in first complete haematological complete remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in ADULT patients where all the following criteria are met:
Treatment criterion (#10) updated
Blinatumomab (BLI4)
The treatment of patients in first complete haematological remission and with minimal residual disease post 1st line induction chemotherapy in B-precursor acute lymphoblastic leukaemia in CHILD patients where all the following criteria have been met:
Treatment criterion (#10) updated
Blinatumomab (BLI5)
The treatment of ADULT patients in first morphological complete remission and without minimal residual disease after line intensive induction and intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemiawhere all the following criteria are met:
Treatment criterion (#11) updated
Blinatumomab (BLI6)
The treatment of POST PUBESCENT CHILDREN in first morphological complete remission and without minimal residual disease after 1st line intensive induction and any indicated intensification chemotherapy for Philadelphia chromosome negative B-cell precursor acute lymphoblastic leukaemia where the following criteria have been met
Treatment criterion (#11) updated
Lenvatinib monotherapy (LNV3)
Treatment of Child-Pugh A locally advanced or metastatic hepatocellular carcinoma where the following criteria are met:
Treatment criteria (#4 and 8) updated
Nivolumab (NIV8a)
Nivolumab monotherapy (with or without initial combination treatment with ipilimumab) for treating unresectable advanced malignant melanoma (form a): REGISTRATION OF START OF NIVOLUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY (WITHOUT INITIAL COMBINATION WITH IPILIMUMAB) OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED NIVOLUMAB MONOTHERAPY AFTER INITIAL COMBINATION WITH IPILIMUMAB (clinicians starting patients on nivolumab plus ipilimumab combination treatment should only use this form after the ipilimumab part of the treatment has been completed). This form comes in 3 parts 1. The first part is for patients who are either scheduled to commence nivolumab monotherapy or who commenced and continue to receive nivolumab monotherapy or who continue to receive nivolumab monotherapy after initial combination treatment with ipilimumab. The second part of the form which must use the same unique Blueteq identifier for those benefitting patients who choose to electively discontinue nivolumab after or more years of treatment. 2. The second part (patient details will automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of nivolumab. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped nivolumab and whom there is disease progression for which the clinician wishes to re- commence nivolumab monotherapy. 3. The third part of the form (patient details will be automatically entered) will only appear once the second part of the form has been approved.
Treatment criterion (#4) updated
Nivolumab and ipilimumab (NIV18)
Nivolumab in combination with ipilimumab for treating advanced melanoma
Treatment criterion (#4) updated
Pembrolizumab (PEMB2)
Pembrolizumab monotherapy for the first line treatment of locally advanced or metastatic non-small cell lung cancer which expresses PD-L1 with a tumour proportion score of at least 50% where the following criteria are met:
Treatment criteria (#6, 8 and 12) updated
Pembrolizumab (PEMB9a)
Pembrolizumab monotherapy for treating unresectable or advanced malignant melanoma (form a): REGISTRATION OF START OF PEMBROLIZUMAB MONOTHERAPY OR OF PREVIOUSLY COMMENCED AND CURRENTLY CONTINUED PEMBROLIZUMAB MONOTHERAPY This form comes in 3 parts. 1. The first part is for patients who are either scheduled to commence pembrolizumab monotherapy or who commenced and continue to receive pembrolizumab monotherapy. 2. The second part of the form which must use the same unique Blueteq identifier is for those benefitting patients who choose to electively discontinue pembrolizumab after 2 or more years of treatment; this second part (patient details be automatically entered) will only appear once the first part of the form is approved and should be completed at the time of elective discontinuation of pembrolizumab. 3. The third part of the form which must use the same unique Blueteq identifier is for those patients registered as having electively and previously stopped pembrolizumab and in whom there is disease progression for which the clinician wishes to re-commence pembrolizumab; this third part of the form (patient details will automatically entered) will only appear once
Treatment criteria (#4 and 10) updated
Sorafenib monotherapy (SOR3)
Treatment of Child-Pugh A locally advanced or metastatic hepatocellular carcinoma where the following criteria met:
Treatment criteria (#4 and 8) updated
Ribociclib in combination with an aromatase inhibitor (RIB3)
Ribociclib in combination with an aromatase inhibitor as adjuvant treatment for high risk hormone receptor-positive and HER2-negative early breast cancer where the following criteria have been met
Moved into routine commissioning - section B of list
Darolutamide in combination with androgen deprivation therapy (ADT) (DARO3)
For the treatment of patients with newly diagnosed metastatic hormone-sensitive prostate cancer who are unsuitable for treatment with docetaxel where the following criteria have been met
Date moving into routine commissioning updated